Showing results (221-230 of 274) with videos related to

Sort By:
Pageof 28
Brain Research|August 17, 1999
Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alphaI L Campbell, T Krucker, S Steffensen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 1, 2010
Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat modelAtique U Ahmed, Cleo E Rolle, Matthew A Tyler, et al.
Biomaterials|November 12, 2013
Fibrin-binding, peptide amphiphile micelles for targeting glioblastomaEun Ji Chung, Yu Cheng, Ramin Morshed, et al.
Behavior Genetics|December 13, 2005
Genome-wide scan of IQ finds significant linkage to a quantitative trait locus on 2qM Luciano, M J Wright, D L Duffy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2012
IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survivalDerek A Wainwright, Irina V Balyasnikova, Alan L Chang, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|May 19, 2025
Predicting medical prognosis in patients with glioblastoma during inpatient rehabilitation using bed mobility functionTomasz Gruchala, Christopher W Lewis, Kathryn Abplanalp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectivesR Costa, B A Carneiro, D A Wainwright, et al.
Pigment Cell & Melanoma Research|January 30, 2016
Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skinJared Klarquist, Jonathan M Eby, Steven W Henning, et al.
Cancer Immunology Research|April 12, 2022
Circadian Regulator CLOCK Drives Immunosuppression in GlioblastomaWenjing Xuan, Wen-Hao Hsu, Fatima Khan, et al.
Oncotarget|December 17, 2017
Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence <i>in situ</i> hybridization (FISH) to select the optimal patients for matched therapy?Young Kwang Chae, Ayush Arya, Lauren Chiec, et al.
Pageof 28